Cargando…
Interleukin-17 Receptor D in Physiology, Inflammation and Cancer
Interleukin-17 receptor D (IL-17RD) is an evolutionarily conserved member of the IL-17 receptor family. Originally identified as a negative regulator of fibroblast growth factor (FGF) signaling under the name of Sef (Similar expression to FGF genes), IL-17RD was subsequently reported to regulate oth...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8021910/ https://www.ncbi.nlm.nih.gov/pubmed/33833999 http://dx.doi.org/10.3389/fonc.2021.656004 |
_version_ | 1783674834100682752 |
---|---|
author | Girondel, Charlotte Meloche, Sylvain |
author_facet | Girondel, Charlotte Meloche, Sylvain |
author_sort | Girondel, Charlotte |
collection | PubMed |
description | Interleukin-17 receptor D (IL-17RD) is an evolutionarily conserved member of the IL-17 receptor family. Originally identified as a negative regulator of fibroblast growth factor (FGF) signaling under the name of Sef (Similar expression to FGF genes), IL-17RD was subsequently reported to regulate other receptor tyrosine kinase signaling pathways. In addition, recent studies have shown that IL-17RD also modulates IL-17 and Toll-like receptor (TLR) signaling. Combined genetic and cell biology studies have implicated IL-17RD in the control of cell proliferation and differentiation, cell survival, lineage specification, and inflammation. Accumulating evidence also suggest a role for IL-17RD in tumorigenesis. Expression of IL-17RD is down-regulated in various human cancers and recent work has shown that loss of IL-17RD promotes tumor formation in mice. However, the exact mechanisms underlying the tumor suppressor function of IL-17RD remain unclear and some studies have proposed that IL-17RD may exert pro-tumorigenic effects in certain contexts. Here, we provide an overview of the signaling functions of IL-17RD and review the evidence for its involvement in cancer. |
format | Online Article Text |
id | pubmed-8021910 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-80219102021-04-07 Interleukin-17 Receptor D in Physiology, Inflammation and Cancer Girondel, Charlotte Meloche, Sylvain Front Oncol Oncology Interleukin-17 receptor D (IL-17RD) is an evolutionarily conserved member of the IL-17 receptor family. Originally identified as a negative regulator of fibroblast growth factor (FGF) signaling under the name of Sef (Similar expression to FGF genes), IL-17RD was subsequently reported to regulate other receptor tyrosine kinase signaling pathways. In addition, recent studies have shown that IL-17RD also modulates IL-17 and Toll-like receptor (TLR) signaling. Combined genetic and cell biology studies have implicated IL-17RD in the control of cell proliferation and differentiation, cell survival, lineage specification, and inflammation. Accumulating evidence also suggest a role for IL-17RD in tumorigenesis. Expression of IL-17RD is down-regulated in various human cancers and recent work has shown that loss of IL-17RD promotes tumor formation in mice. However, the exact mechanisms underlying the tumor suppressor function of IL-17RD remain unclear and some studies have proposed that IL-17RD may exert pro-tumorigenic effects in certain contexts. Here, we provide an overview of the signaling functions of IL-17RD and review the evidence for its involvement in cancer. Frontiers Media S.A. 2021-03-23 /pmc/articles/PMC8021910/ /pubmed/33833999 http://dx.doi.org/10.3389/fonc.2021.656004 Text en Copyright © 2021 Girondel and Meloche http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Girondel, Charlotte Meloche, Sylvain Interleukin-17 Receptor D in Physiology, Inflammation and Cancer |
title | Interleukin-17 Receptor D in Physiology, Inflammation and Cancer |
title_full | Interleukin-17 Receptor D in Physiology, Inflammation and Cancer |
title_fullStr | Interleukin-17 Receptor D in Physiology, Inflammation and Cancer |
title_full_unstemmed | Interleukin-17 Receptor D in Physiology, Inflammation and Cancer |
title_short | Interleukin-17 Receptor D in Physiology, Inflammation and Cancer |
title_sort | interleukin-17 receptor d in physiology, inflammation and cancer |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8021910/ https://www.ncbi.nlm.nih.gov/pubmed/33833999 http://dx.doi.org/10.3389/fonc.2021.656004 |
work_keys_str_mv | AT girondelcharlotte interleukin17receptordinphysiologyinflammationandcancer AT melochesylvain interleukin17receptordinphysiologyinflammationandcancer |